ÄÉÃ×¶þÑõ»¯¹è(SiO2),nano-silica(SiO2)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
5ä庺·À¼º¼×ËØ,5-bromotetrandrineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
±ÇÑÊÖ×Áö,nasopharyngeal neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÌØÕ÷ѡȡ,feature selectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ʳ¹Ü°©,Esophageal carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂãСÊó,nude miceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼ÓÈÈζÈ,Heating TemperatureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
θÖ×Áö/Ò©ÎïÁÆ·¨,stomach neoplasms/drug therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÏÙÑùÄÒÐÔ,adenoid cysticÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÖÀà¹æÔò,classification ruleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
siRNA,small interfering RNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼¦Æ¶Ñª²¡¶¾,chicken anemia virusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ʵÌåÖ×Áö,solid tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Çú¹Å¾úËØA,trichostatin AÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈâÁöÑù°©,sarcomatoid carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
DNA½áºÏµ°°×ÖÊÀà,DNA-binding proteinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö΢»·¾³,Tumor microenvironmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶¸Âö³å,Steep pulseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Á×Ëáø»îÐÔ,phosphatase activityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×éµ°°×È¥ÒÒõ£»¯Ã¸ÒÖÖÆ¼Á,Histone deacetylase inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûÖÜÆÚµ°°×B1,Cyclin B1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûÔöÖ³ºË¿¹Ô,PCNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°×µ°°×΢Çò,albumin microspheresÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Î°©Ï¸°ûÖê,lung cancer cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûÉãÈ¡,Cellular uptakeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
MVD,microvessel densityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ì©°²ÊÐ,Taian CityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐÂÓàÊÐ,Xinyu cityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
BGC-823ϸ°û,BGC-823 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ß·¢Çø,high incidence areaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÊÈÉñ¾ÇÖÏ®,perineural invasionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼à²â×ÊÁÏ,monitoring dataÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶àÒ©ÄÍÒ©»ùÒò,multidrug resistance geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ó¤¶ùË«Æç¸Ë¾ú,bifidobacterium infantisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°©ÐÔ¶ñ²¡ÖÊ,cancer cachexiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÊÜÌåÏÔÏñ,Receptor imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´óãëºÓ,Dawen RiverÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ѪÖ×ÁöÆÁÕÏ,blood-tumor barrierÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·¦ÑõÏÔÏñ,hypoxia imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·´ÒåÏÔÏñ,antisense imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
L-°±»ùËáÑõ»¯Ã¸,L-amino acid oxidaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
³É¿×,pore-formingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»î»¯µ°°×-1,activator protein-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÏÔÏñ,Tumor imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Apoptin»ùÒò,apoptin geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÒÆÖ²,Neoplasm transplantationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô߲߸¢ù,Protoporphyrin ¢ùÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µòÍöËØ»ùÒò,Apoptin geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö·¦Ñõ,tumor hypoxiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÏÙ²¡¶¾¸ÐȾ,adenovirus infectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸±Ö×Áö×ÛºÏÕ÷,paraneoplastic syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éù¶¯Á¦Ñ§ÁÆ·¨,sonodynamic therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°ûà×à¤ÍѰ±Ã¸»ùÒò,cytosine deaminase geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
p53mRNA,p53 mRNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉàÁÛ״ϸ°û°©,tongue squamous cell carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
F10»ùÒò,F10 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂÈͨµÀ×è¶Ï¼Á,chloride channel blockerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ßÄںɸѡ,high content screeningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö÷¶¯°ÐÏò,Active targetingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
SGC7901/VCRϸ°û,SGC7901/VCR cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·´ÒåºËËá¼¼Êõ,antisense nucleic acid technologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Èí×éÖ¯Ö×Áö,soft tissue neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×éÖ¯¼äÖ²Èë,interstitial implantationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô¤ºóÖ¸±ê,Prognostic factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°û½Çµ°°×18,cytokeratin 18Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
DADS,diallyl disulfideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹ÓÕ±äÒ©,antimutagenic agentsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
hTRT»ùÒò,hTRT geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¦Ä-°±»ùÒÒõ£±ûËá,¦Ä-aminolevulinic acidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Æ÷¹Ù¼ÁÁ¿,Organ DoseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Ö×Ó°ÐÏòÖÎÁÆ,Molecular targeted therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×éµ°°×ÍÑÒÒõ£Ã¸ÒÖÖÆ¼Á,Histone Deacetylase InhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö·ÖÀà,tumor classificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
L-meq»ùÒò,L-meq geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼ä½Ó±ê¼Ç,indirect labelingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ȱÑõ·´Ó¦Ôª¼þ,hypoxia response elementsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹²Í¬ÅàÑø¼¼Êõ,coculture techniquesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöѪ¹Ü,Tumor vesselÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûÁÑÍö,mitotic cell deathÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÔ¤·À,cancer preventionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½ü½»F344,inbred F344Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Egr-1»ùÒò,Egr-1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
S-180ÈâÁö,S-180 sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
È˺ìϸ°ûĤ,human erythrocyte membraneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
EhrlichÁö,Ehrlich tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´úл»î»¯,metabolic activationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½üºìÍâ¼¼Êõ,NIR technologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°¬Êϸ¹Ë®Áö,ehrlich ascites tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
PRL-3,PRL-3 GeneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×Ôɱ»ùÒòÁÆ·¨,Suicide Gene TherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒìÖÖ¿¹Ô,XenoantigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ßÅßá3-²Ýõ£°·ÑÜÉúÎï,derivative of indol-3-glyoxylic acid amideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
S180ºÉÁöСÊó,S180 tumor-bearing miceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×éµ°°×ÒÒõ£»ù×ªÒÆÃ¸,Histone acetyltransferaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÇÖÏ®×ªÒÆ,Tumor invasion and metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÃâÒßÌÓÒÝ,tumor immune escapeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áöϸ°ûÇ¨ÒÆ,Tumor cell migrationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
θ°©Ï¸°ûϵ,gastric cancer cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÎÏÙ°©A549ϸ°û,lung adenocarcinoma cell line A549Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
H-ras»ùÒò,H-ras geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«

|